Work

138P TALAPRO-1: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin

Year: 2020

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.259

Authors: N. Mehra, K. Fizazi, A.D. Laird, P. Barthélémy, R. Delva, T. Dorff, M. Maruzzo, A. Stirling, J-P. Machiels, H. Dumez, V. Renard, L.A. Albacker, J. Hopkins, H-C. Chen, M. Mata, N. Di Santo, C.G. Healy, I.M. van Oort, C. Buttigliero, J.S. de Bono

Institutions: Radboud University Medical Center, Université Paris-Saclay, Institut Gustave Roussy, Pfizer (United States), Institut de Cancérologie Strasbourg, Institut de Cancérologie de l'Ouest, University of Southern California, USC Norris Comprehensive Cancer Center, Istituto Oncologico Veneto, Wesley Hospital, Cliniques Universitaires Saint-Luc, Universitair Ziekenhuis Leuven, AZ Sint-Lucas, Foundation Medicine (United States), Ospedale San Luigi Gonzaga, University of Turin, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3089319931

FWCI: 0.181

Cites:

Cited by: 2

Related to: 10